Sunosi (solriamfetol) – To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.
SUNOSI DOSAGE AND ADMINISTRATION
- Administer once daily upon awakening. Avoid administration within 9 hours of planned bedtime because of the potential to interfere with sleep.
- Starting dose for patients with narcolepsy: 75 mg once daily.
- Starting dose for patients with OSA: 37.5 mg once daily.
- Dose may be increased at intervals of at least 3 days.
- Maximum dose is 150 mg once daily.
- Renal impairment
- Moderate impairment: Starting dose is 37.5 mg once daily.
- May increase to 75 mg once daily after at least 7 days.
- Severe impairment: Starting dose and maximum dose is 37.5 mg once daily.
- End stage renal disease (ESRD): Not recommended.
SUNOSI INDICATIONS AND USAGE
SUNOSI is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).
Limitations of Use
SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities.
SUNOSI ADVERSE REACTIONS
Most common adverse reactions (≥5% and greater than placebo): headache, nausea, decreased appetite, insomnia, and anxiety
SUNOSI DRUG INTERACTIONS
Drugs that Increase Blood Pressure and/or Heart Rate and Dopaminergic Drugs: Use caution when co-administering with SUNOSI